Oramed Pharmaceuticals
ORMP
51 hedge funds and large institutions have $15.4M invested in Oramed Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 13 closing their positions.
65% more call options, than puts
Call options by funds: $43K | Put options by funds: $26K
27% more capital invested
Capital invested by funds: $12.1M → $15.4M (+$3.3M)
0.04% more ownership
Funds ownership: 12.95% → 12.99% (+0.04%)
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
9% less funds holding
Funds holding: 56 → 51 (-5)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$921K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$835K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$461K |
| 4 |
VF
Virtu Financial
New York
|
+$64.8K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$57.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$1.17M |
| 2 |
Renaissance Technologies
New York
|
-$612K |
| 3 |
Morgan Stanley
New York
|
-$234K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$87.7K |
| 5 |
Squarepoint
New York
|
-$78.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GRP
51
Global Retirement Partners
San Rafael,
California
| $292 | – | – | – |
|
|
52
Citadel Advisors
Miami,
Florida
| – | -$87.7K | -31,347 | Closed |
|
|
XT
53
XTX Topco
George Town,
Cayman Islands
| – | -$40K | -17,325 | Closed |
|
|
AG
54
Algert Global
San Francisco,
California
| – | -$34K | -14,680 | Closed |
|
|
HF
55
HRT Financial
New York
| – | -$25K | -11,165 | Closed |
|
56
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$21K | -9,244 | Closed |
|
|
A
57
AJOVista
Boston,
Massachusetts
| – | -$19.4K | -8,390 | Closed |
|
|
BCM
58
Bourgeon Capital Management
Darien,
Connecticut
| – | -$13K | -5,627 | Closed |
|
|
LA
59
LM Advisors
San Diego,
California
| – | -$5.78K | -2,500 | Closed |
|
|
QT
60
Quantbot Technologies
New York
| – | -$5.31K | -2,300 | Closed |
|
61
Fidelity Investments
Boston,
Massachusetts
| – | -$2.08K | -900 | Closed |
|
62
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$852 | -369 | Closed |
|
|
BBHC
63
Brown Brothers Harriman & Co
New York
| – | -$18 | -8 | Closed |
|
64
BNP Paribas Financial Markets
Paris,
France
| – | -$5 | -2 | Closed |
|
ORMP Hedge Fund Activity: Q1 2024 in Review
51 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q1 2024, worth a combined $15.4M — up 27% from $12.1M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ORMP and 8 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 13 added.
The largest buyer was Murchinson, adding an estimated $921K. The largest seller was BML Capital Management, cutting an estimated $1.17M.
- 51 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q1 2024, down from 56 in Q4 2023.
- Funds reported $15.4M of Oramed Pharmaceuticals stock for Q1 2024, up 27% quarter-over-quarter.
- 8 funds opened new Oramed Pharmaceuticals positions in Q1 2024 and 13 closed out, a net change of -5 holders.
- The largest Oramed Pharmaceuticals buyer in Q1 2024 was Murchinson, an estimated $921K added.
- The largest Oramed Pharmaceuticals seller in Q1 2024 was BML Capital Management, an estimated $1.17M sold.
Based on aggregated 13F filings for Q1 2024.